MDGL logo

MDGL
Madrigal Pharmaceuticals Inc

6,962
Mkt Cap
$11.76B
Volume
4,217.00
52W High
$615.00
52W Low
$265.00
PE Ratio
-39.86
MDGL Fundamentals
Price
$513.80
Prev Close
$510.26
Open
$510.44
50D MA
$493.50
Beta
0.81
Avg. Volume
276,802.77
EPS (Annual)
-$12.85
P/B
21.63
Rev/Employee
$1.05M
$12,423.38
Loading...
Loading...
News
all
press releases
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
MDGL stock up on better-than-expected first-quarter results on account of robust Rezdiffra sales, driven by strong MASH demand and rising patient adoption.
Zacks·6d ago
News Placeholder
More News
News Placeholder
Madrigal Pharmaceuticals Q1 Earnings Call Highlights
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported first-quarter 2026 net sales of $311.3 million as executives said demand for its MASH therapy Rezdiffra continued to build in a market they described as still early in development. On the company's earnings call, management highlighted patient growth...
MarketBeat·7d ago
News Placeholder
Madrigal Pharmaceuticals (NASDAQ:MDGL) Receives Buy Rating from HC Wainwright
HC Wainwright reiterated a "buy" rating and set a $620.00 price objective on shares of Madrigal Pharmaceuticals in a research report on Wednesday...
MarketBeat·7d ago
News Placeholder
Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates
Madrigal (MDGL) delivered earnings and revenue surprises of +9.97% and +3.38%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7d ago
News Placeholder
Madrigal Pharmaceuticals Posts Wider Loss In Q1
(RTTNews) - Wednesday, Madrigal Pharmaceuticals, Inc. (MDGL) announced its first-quarter financial results, reporting a net loss of $94.4 million, or $3.25 a share, compared to $73.2 million, or $2.61 a share, in the previous year...
Nasdaq News: Markets·7d ago
News Placeholder
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (NASDAQ: MDGL) for ARO-PNPLA3, Arrowheads clinical stage RNA...
Business Wire·8d ago
News Placeholder
Vanguard Group Inc. Trims Stake in Madrigal Pharmaceuticals, Inc. $MDGL
Vanguard Group Inc. reduced its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 0.2% in the fourth quarter, according to its most recent 13F filing with the...
MarketBeat·11d ago
News Placeholder
Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for
CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·13d ago
News Placeholder
Madrigal (MDGL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Madrigal (MDGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·14d ago
News Placeholder
Madrigal Pharmaceuticals (MDGL) Expected to Announce Quarterly Earnings on Wednesday
Madrigal Pharmaceuticals (NASDAQ:MDGL) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-madrigal-pharmaceuticals-inc-stock...
MarketBeat·14d ago
<
1
2
...
>

Latest MDGL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.